123 related articles for article (PubMed ID: 20432331)
1. What treatment should we use if drugs fail for OAB; and, what really works after drugs?
Bosch JL; Kelleher C; van Kerrebroeck PE; Schurch B
Neurourol Urodyn; 2010 Apr; 29(4):658-61. PubMed ID: 20432331
[TBL] [Abstract][Full Text] [Related]
2. [Update on the second line management of idiopathic overactive bladder].
Chartier-Kastler E; Castro-Diaz D; De Ridder D; Everaert K; Sievert KD; Spinelli M; van Kerrebroeck P
Prog Urol; 2009 Sep; 19(8):530-7. PubMed ID: 19699450
[TBL] [Abstract][Full Text] [Related]
3. [Guidelines for treatment of urinary incontinence in women due to refractory idiopathic vesical hyperactivity with botulinum toxin A].
Peyrat L; Ragni E;
Prog Urol; 2010 Feb; 20 Suppl 2():S170-3. PubMed ID: 20403570
[TBL] [Abstract][Full Text] [Related]
4. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
Tubaro A; Puccini F; De Nunzio C
Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
[TBL] [Abstract][Full Text] [Related]
5. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.
Leong RK; De Wachter SG; van Kerrebroeck PE
Urol Int; 2010; 84(3):245-53. PubMed ID: 20389150
[TBL] [Abstract][Full Text] [Related]
6. Refractory neurogenic detrusor overactivity.
Cruz F; Silva C
Int J Clin Pract Suppl; 2006 Dec; (151):22-6. PubMed ID: 17169007
[TBL] [Abstract][Full Text] [Related]
7. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units.
Cohen BL; Barboglio P; Rodriguez D; Gousse AE
Neurourol Urodyn; 2009; 28(3):205-8. PubMed ID: 19058190
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.
Siddiqui NY; Amundsen CL; Visco AG; Myers ER; Wu JM
J Urol; 2009 Dec; 182(6):2799-804. PubMed ID: 19837427
[TBL] [Abstract][Full Text] [Related]
10. Constructing trials to show whether urodynamic studies are necessary in lower urinary tract dysfunction.
Bosch JL; Cardozo L; Hashim H; Hilton P; Oelke M; Robinson D
Neurourol Urodyn; 2011 Jun; 30(5):735-40. PubMed ID: 21661022
[TBL] [Abstract][Full Text] [Related]
11. Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder.
Sahai A; Khan MS; Le Gall N; Dasgupta P;
Urology; 2008 Mar; 71(3):455-9. PubMed ID: 18342186
[TBL] [Abstract][Full Text] [Related]
12. [Neuromodulation as a treatment for overactive bladder syndrome].
Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin in the treatment of OAB, BPH, and IC.
Smith CP
Toxicon; 2009 Oct; 54(5):639-46. PubMed ID: 19268490
[TBL] [Abstract][Full Text] [Related]
14. Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity.
Schmid DM; Roy S; Sulser T; Scheiner D
BJU Int; 2008 Jul; 102 Suppl 1():7-10. PubMed ID: 18665972
[TBL] [Abstract][Full Text] [Related]
15. Changing treatments for overactive bladder.
Waine E; Stott M
Nurs Times; 2008 Oct 14-20; 104(41):45-8. PubMed ID: 18979960
[TBL] [Abstract][Full Text] [Related]
16. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?
Sahai A; Sangster P; Kalsi V; Khan MS; Fowler CJ; Dasgupta P
BJU Int; 2009 Mar; 103(5):630-4. PubMed ID: 18990156
[TBL] [Abstract][Full Text] [Related]
17. Experience with injections of botulinum toxin type A into the detrusor muscle.
Miyagawa I; Watanabe T; Isoyama T; Honda M; Kobayasi N; Hikita K; Saito M; Hirakawa S
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S24-6. PubMed ID: 20094947
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children.
Marte A; Borrelli M; Sabatino MD; Balzo BD; Prezioso M; Pintozzi L; Nino F; Parmeggiani P
Eur J Pediatr Surg; 2010 May; 20(3):153-7. PubMed ID: 20112186
[TBL] [Abstract][Full Text] [Related]
19. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
[TBL] [Abstract][Full Text] [Related]
20. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.
Kuo HC
Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
